ETNB - NASDAQ

89bio, Inc.

ETNB·NASDAQ

$14.84

+0.0000%

HealthcareBiotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.20B

EPS-3.5100

P/E Ratio-2.23

Earnings Date11/06/2025

etnb

Shares Outstanding

Last Annual Value

104.71M

3-Year CAGR

73%

5-Year CAGR

58%

10-Year CAGR

37%

Adjust for Inflation

89bio, Inc. Competitors Analysis of shares-outstanding

ETNB · NASDAQ

Company	shares-outstanding	CAGR 3Y	CAGR 5Y	CAGR 10Y
89bio, Inc. NASDAQ:ETNB	104.71M	13.7%	39.1%	N/A
Agios Pharmaceuticals, Inc. NASDAQ:AGIO	57.97M	1.4%	-0.8%	4.0%
Beam Therapeutics Inc. NASDAQ:BEAM	98.91M	8.6%	9.0%	N/A
Cogent Biosciences, Inc. NASDAQ:COGT	67.60M	-5.3%	11.8%	24.8%
Denali Therapeutics Inc. NASDAQ:DNLI	175.46M	8.5%	7.6%	39.2%
ImmunityBio, Inc. NASDAQ:IBRX	919.86M	21.8%	18.8%	10.8%
Liquidia Corporation NASDAQ:LQDA	86.06M	9.8%	11.6%	25.9%
Ocular Therapeutix, Inc. NASDAQ:OCUL	187.24M	29.8%	17.9%	22.4%
Arcus Biosciences, Inc. NYSE:RCUS	107.40M	13.2%	7.7%	15.9%
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX	447.45M	29.1%	21.3%	N/A

89bio, Inc. Fair Value Envelope

ETNB · NASDAQ

Our analysis suggests that ETNB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.84, this represents a potential HIDDEN relative to our calculated worth for 89bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $14.84

Related Guides

Blog Categories

Continue your ETNB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.